Fisher Asset Management LLC Buys 8,298 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Fisher Asset Management LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 112.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,696 shares of the medical research company’s stock after purchasing an additional 8,298 shares during the period. Fisher Asset Management LLC’s holdings in IQVIA were worth $3,085,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the company. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA during the third quarter valued at approximately $27,000. Synergy Asset Management LLC bought a new position in IQVIA in the 4th quarter valued at approximately $33,000. Avior Wealth Management LLC boosted its stake in IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 87 shares during the last quarter. Assetmark Inc. increased its holdings in shares of IQVIA by 612.5% in the 3rd quarter. Assetmark Inc. now owns 228 shares of the medical research company’s stock worth $54,000 after purchasing an additional 196 shares in the last quarter. Finally, Ashton Thomas Securities LLC purchased a new position in shares of IQVIA in the third quarter worth $57,000. 89.62% of the stock is owned by hedge funds and other institutional investors.

IQVIA Stock Performance

Shares of NYSE IQV opened at $186.04 on Thursday. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 1 year low of $179.28 and a 1 year high of $261.73. The firm has a fifty day moving average price of $198.24 and a 200-day moving average price of $213.66. The stock has a market cap of $32.80 billion, a PE ratio of 24.81, a price-to-earnings-growth ratio of 1.99 and a beta of 1.50.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on IQV. JPMorgan Chase & Co. reduced their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Stephens began coverage on shares of IQVIA in a report on Friday, December 20th. They set an “overweight” rating and a $250.00 price objective for the company. Royal Bank of Canada restated an “outperform” rating and set a $270.00 price objective on shares of IQVIA in a research report on Monday, February 10th. UBS Group decreased their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating for the company in a research note on Friday, February 7th. Finally, Barclays dropped their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Four equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.